Tassies D - Search Results

1

Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response.

Pinazo MJ, Posada Ede J, Izquierdo L, Tassies D, Marques AF, de Lazzari E, Aldasoro E, Muñoz J, Abras A, Tebar S, Gallego M, de Almeida IC, Reverter JC, Gascon J. Pinazo MJ, et al. Among authors: tassies d. PLoS Negl Trop Dis. 2016 Jan 4;10(1):e0004269. doi: 10.1371/journal.pntd.0004269. eCollection 2016 Jan. PLoS Negl Trop Dis. 2016. PMID: 26727000 Free PMC article.

2

Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin.

Espinosa G, Font J, Tàssies D, Vidaller A, Deulofeu R, López-Soto A, Cervera R, Ordinas A, Ingelmo M, Reverter JC. Espinosa G, et al. Among authors: tassies d. Am J Med. 2002 Jan;112(1):37-43. doi: 10.1016/s0002-9343(01)01048-8. Am J Med. 2002. PMID: 11812405

3

Vascular involvement in Behçet's disease.

Espinosa G, Cervera R, Reverter JC, Tàssies D, Font J, Ingelmo M. Espinosa G, et al. Among authors: tassies d. Isr Med Assoc J. 2002 Aug;4(8):614-6. Isr Med Assoc J. 2002. PMID: 12183866 Free article. Review. No abstract available.

4

Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent.

García-Segarra G, Espinosa G, Tassies D, Oriola J, Aibar J, Bové A, Castro P, Reverter JC, Nicolás JM. García-Segarra G, et al. Among authors: tassies d. Intensive Care Med. 2007 Aug;33(8):1354-62. doi: 10.1007/s00134-007-0695-y. Epub 2007 May 31. Intensive Care Med. 2007. PMID: 17541549

5

Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.

Tàssies D, Roqué M, Monteagudo J, Martorell T, Sionis A, Arzamendi D, Heras M, Reverter JC. Tàssies D, et al. Thromb Res. 2009 Nov;124(5):614-8. doi: 10.1016/j.thromres.2009.07.004. Epub 2009 Aug 21. Thromb Res. 2009. PMID: 19699511

6

Hypercoagulability biomarkers in Trypanosoma cruzi -infected patients.

Pinazo MJ, Tàssies D, Muñoz J, Fisa R, Posada Ede J, Monteagudo J, Ayala E, Gállego M, Reverter JC, Gascon J. Pinazo MJ, et al. Among authors: tassies d. Thromb Haemost. 2011 Oct;106(4):617-23. doi: 10.1160/TH11-04-0251. Epub 2011 Aug 25. Thromb Haemost. 2011. PMID: 21866301

7

Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis.

Raffa S, Reverter JC, Seijo S, Tassies D, Abraldes JG, Bosch J, García-Pagán JC. Raffa S, et al. Among authors: tassies d. Clin Gastroenterol Hepatol. 2012 Jan;10(1):72-8. doi: 10.1016/j.cgh.2011.09.010. Epub 2011 Sep 23. Clin Gastroenterol Hepatol. 2012. PMID: 21946303

8

Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy.

Mejía JC, Espinosa G, Tàssies D, Reverter JC, Cervera R. Mejía JC, et al. Among authors: tassies d. Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S67-71. Epub 2014 Jul 17. Clin Exp Rheumatol. 2014. PMID: 25068444

9

Procoagulant microparticles are increased in patients with Behçet's disease but do not define a specific subset of clinical manifestations.

Mejía JC, Ortiz T, Tàssies D, Solanich X, Vidaller A, Cervera R, Reverter JC, Espinosa G. Mejía JC, et al. Among authors: tassies d. Clin Rheumatol. 2016 Mar;35(3):695-9. doi: 10.1007/s10067-015-2903-4. Epub 2015 Feb 26. Clin Rheumatol. 2016. PMID: 25711877

10

Enzyme-linked immunosorbent assays for therapeutic drug monitoring coumarin oral anticoagulants in plasma.

Salvador JP, Tassies D, Reverter JC, Marco MP. Salvador JP, et al. Among authors: tassies d. Anal Chim Acta. 2018 Oct 22;1028:59-65. doi: 10.1016/j.aca.2018.04.042. Epub 2018 Apr 21. Anal Chim Acta. 2018. PMID: 29884354

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

114 results

Search Page